{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:23:16Z","timestamp":1794565396600,"version":"4.9.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C31277 \/A25887"],"award-info":[{"award-number":["C31277 \/A25887"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR \/T029226\/1"],"award-info":[{"award-number":["MR \/T029226\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106917\/Z\/15\/Z"],"award-info":[{"award-number":["106917\/Z\/15\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001273","name":"Children with Cancer UK","doi-asserted-by":"publisher","award":["16-230"],"award-info":[{"award-number":["16-230"]}],"id":[{"id":"10.13039\/501100001273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017170","name":"Thailand Science Research and Innovation","doi-asserted-by":"publisher","award":["RGNS 65-040"],"award-info":[{"award-number":["RGNS 65-040"]}],"id":[{"id":"10.13039\/501100017170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024597","name":"Office of the Permanent Secretary, Ministry of Higher Education, Science, Research and Innovation, Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024597","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010438","name":"Cancer Research UK London Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016204","name":"Ministry of Higher Education, Science, Research and Innovation, Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016204","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biomaterials.2026.124286","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:24:23Z","timestamp":1778196263000},"page":"124286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Harnessing prophylactic vaccines for targeted cancer immunotherapy by phage-guided delivery of cognate antigens to tumors"],"prefix":"10.1016","volume":"334","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-8883","authenticated-orcid":false,"given":"Sajee","family":"Waramit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keittisak","family":"Suwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5163-4121","authenticated-orcid":false,"given":"Alara","family":"K\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surachet","family":"Benjathummarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Cencioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ashfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-1357","authenticated-orcid":false,"given":"Simon J.","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1119-5686","authenticated-orcid":false,"given":"Amin","family":"Hajitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.biomaterials.2026.124286_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2026.124286_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115306","article-title":"Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade","volume":"209","author":"Choi","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124286_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12672-022-00491-4","article-title":"Cancer vaccines: past, present and future; a review article","volume":"13","author":"Grimmett","year":"2022","journal-title":"Discov. Oncol."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124286_bib4","article-title":"Recent advances in cancer immunotherapy with a focus on FDA-Approved vaccines and neoantigen-based vaccines","volume":"11","author":"Hargrave","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124286_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.hoc.2018.12.001","article-title":"Cancer vaccines","volume":"33","author":"DeMaria","year":"2019","journal-title":"Hematol. Oncol. Clin. N. Am."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124286_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.biomaterials.2026.124286_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01555-w","article-title":"HBsAg-tagged tumour vaccine system eliminates solid tumours through virus-specific memory T cells","author":"Wang","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124286_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jcp.24791","article-title":"Gene therapies for cancer: strategies, challenges and successes","volume":"230","author":"Das","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.biomaterials.2026.124286_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105834","article-title":"Viral and non-viral vectors in gene therapy: current state and clinical perspectives","volume":"118","author":"Geng","year":"2025","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124286_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cell.2006.02.042","article-title":"A hybrid vector for ligand-directed tumor targeting and molecular imaging","volume":"125","author":"Hajitou","year":"2006","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124286_bib11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1473-3099(14)70867-9","article-title":"The phage revolution against antibiotic resistance","volume":"14","author":"Asavarut","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124286_bib12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4155\/tde.14.58","article-title":"Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma","volume":"5","author":"Asavarut","year":"2014","journal-title":"Ther. Deliv."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124286_bib13","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1073\/pnas.0712184105","article-title":"A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging","volume":"105","author":"Hajitou","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124286_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004972","article-title":"Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature","volume":"4","author":"Paoloni","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124286_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cncr.24001","article-title":"Tumor vasculature-targeted delivery of tumor necrosis factor-alpha","volume":"115","author":"Tandle","year":"2009","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124286_bib16","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1535-7163.MCT-09-0110","article-title":"A heterotypic bystander effect for tumor cell killing after adeno-associated virus\/phage-mediated, vascular-targeted suicide gene transfer","volume":"8","author":"Trepel","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124286_bib17","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1073\/pnas.1525709113","article-title":"AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas","volume":"113","author":"Smith","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124286_bib18","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202115418","article-title":"Systemically targeted cancer immunotherapy and gene delivery using transmorphic particles","volume":"14","author":"Asavarut","year":"2022","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124286_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41596-024-01040-9","article-title":"Construction and utilization of a new generation of bacteriophage-based particles, or TPA, for guided systemic delivery of nucleic acids to tumors","volume":"21","author":"Gay","year":"2026","journal-title":"Nat. Protoc."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124286_bib20","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1158\/1535-7163.MCT-12-0587","article-title":"Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression","volume":"11","author":"Kia","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124286_bib21","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3390\/v5102561","article-title":"Inhibition of histone deacetylation and DNA methylation improves gene expression mediated by the adeno-associated virus\/phage in cancer cells","volume":"5","author":"Kia","year":"2013","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124286_bib22","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708492","article-title":"Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma","volume":"11","author":"Przystal","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124286_bib23","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1021\/mp3002733","article-title":"RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis","volume":"9","author":"Danhier","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2026.124286_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104100","article-title":"(177)Lu-labeled cyclic RGD peptide as an imaging and targeted radionuclide therapeutic agent in non-small cell lung cancer: biological evaluation and preclinical study","volume":"102","author":"Pirooznia","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124286_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide in cancer targeting: benefits, challenges, solutions, and possible integrin-RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med."},{"issue":"43","key":"10.1016\/j.biomaterials.2026.124286_bib26","doi-asserted-by":"crossref","first-page":"35849","DOI":"10.1074\/jbc.M112.369389","article-title":"Clathrin-mediated endocytosis and subsequent endo-lysosomal trafficking of adeno-associated virus\/phage","volume":"287","author":"Stoneham","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"37","key":"10.1016\/j.biomaterials.2026.124286_bib27","doi-asserted-by":"crossref","first-page":"18571","DOI":"10.1073\/pnas.1906653116","article-title":"Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer","volume":"116","author":"Suwan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124286_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124286_bib29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"issue":"15","key":"10.1016\/j.biomaterials.2026.124286_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153802","article-title":"Repurposing ferumoxytol as a breast cancer-associated macrophage tracer with five-dimensional quantitative [Fe]MRI of SPION dynamics","volume":"13","author":"Sillerud","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biomaterials.2026.124286_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65145","article-title":"Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer","volume":"10","author":"Staquicini","year":"2021","journal-title":"eLife"},{"issue":"16","key":"10.1016\/j.biomaterials.2026.124286_bib32","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1038\/sj.onc.1202126","article-title":"FGF-3 and FGF-4 elicit distinct oncogenic properties in mouse mammary myoepithelial cells","volume":"17","author":"Hajitou","year":"1998","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124286_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/v13122343","article-title":"Targeting human osteoarthritic chondrocytes with ligand directed bacteriophage-based particles","volume":"13","author":"Chongchai","year":"2021","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124286_bib34","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/eji.200737672","article-title":"Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei","volume":"38","author":"Reyes-Sandoval","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124286_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044943","article-title":"T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein","volume":"7","author":"Forbes","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2026.124286_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/bs.mcb.2024.10.011","article-title":"Splenocytes antitumor cytotoxicity assessment after prophylactic vaccination or drug treatment of tumor-bearing mice","volume":"191","author":"Calvillo-Rodriguez","year":"2025","journal-title":"Methods Cell Biol."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124286_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102700","article-title":"Protocol for the expansion of mouse immune effector cells for in vitro and in vivo studies","volume":"4","author":"Look","year":"2023","journal-title":"STAR Protoc."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124286_bib38","article-title":"Targeted treatment of chondrosarcoma with a bacteriophage-based particle delivering a secreted tumor necrosis factor-related apoptosis-inducing ligand","volume":"32","author":"Chongchai","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124286_bib39","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/labinvest.2009.91","article-title":"Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma","volume":"89","author":"Boivin","year":"2009","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124286_bib40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/cdd.2017.169","article-title":"How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124286_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-065X.2010.00952.x","article-title":"Molecular mechanisms by which T-bet regulates T-helper cell commitment","volume":"238","author":"Miller","year":"2010","journal-title":"Immunol. Rev."},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124286_bib42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nri.2017.75","article-title":"The regulation of immune tolerance by FOXP3","volume":"17","author":"Lu","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124286_bib43","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.4049\/jimmunol.1900662","article-title":"Regulatory T cell development in the thymus","volume":"203","author":"Owen","year":"2019","journal-title":"J. Immunol."},{"issue":"Pt 20","key":"10.1016\/j.biomaterials.2026.124286_bib44","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1242\/jcs.00739","article-title":"Apoptosis - the p53 network","volume":"116","author":"Haupt","year":"2003","journal-title":"J. Cell Sci."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124286_bib45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjp.2008.349","article-title":"Viral vectors: from virology to transgene expression","volume":"157","author":"Bouard","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124286_bib46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nprot.2007.51","article-title":"Design and construction of targeted AAVP vectors for mammalian cell transduction","volume":"2","author":"Hajitou","year":"2007","journal-title":"Nat. Protoc."},{"issue":"5158","key":"10.1016\/j.biomaterials.2026.124286_bib47","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin alpha v beta 3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"issue":"5349","key":"10.1016\/j.biomaterials.2026.124286_bib48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.279.5349.377","article-title":"Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model","volume":"279","author":"Arap","year":"1998","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124286_bib49","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1089\/ars.2009.2485","article-title":"Role of the unfolded protein response regulator GRP78\/BiP in development, cancer, and neurological disorders","volume":"11","author":"Wang","year":"2009","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.biomaterials.2026.124286_bib50","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.biomaterials.2026.124286_bib51","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1158\/0008-5472.CAN-05-4441","article-title":"Selection of tumor-binding ligands in cancer patients with phage display libraries","volume":"66","author":"Krag","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124286_bib52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.omtn.2018.04.012","article-title":"Thermoresponsive bacteriophage nanocarrier as a gene delivery vector targeted to the gastrointestinal tract","volume":"12","author":"Namdee","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226003108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226003108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:23:40Z","timestamp":1794561820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226003108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":52,"alternative-id":["S0142961226003108"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124286","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing prophylactic vaccines for targeted cancer immunotherapy by phage-guided delivery of cognate antigens to tumors","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"124286"}}